Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. LMRI
LMRI logo

LMRI Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Lumexa Imaging Holdings Inc (LMRI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
9.490
1 Day change
0.85%
52 Week Range
19.450
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Lumexa Imaging Holdings Inc (LMRI) does not present a compelling buy opportunity for a beginner investor with a long-term focus at this time. The stock has shown recent volatility with a significant price drop in pre-market and post-market trading, and analysts have been lowering price targets due to concerns about growth and cash flow. Additionally, there are no strong positive catalysts, trading signals, or recent news to support a bullish case. A hold is recommended until more favorable conditions arise.

Technical Analysis

The MACD is positively contracting above 0, indicating a slight bullish momentum, but the RSI is neutral at 63.396, suggesting no clear overbought or oversold conditions. Moving averages are converging, and the stock is trading near its pivot level of 9.013, with key support at 8.2 and resistance at 9.827. Overall, the technical indicators do not suggest a strong buy signal.

Positive Catalysts

  • NULL identified. There is no recent news or significant insider/hedge fund activity to act as a positive catalyst.

Neutral/Negative Catalysts

  • Analysts have been lowering price targets due to concerns about growth, cash flow, and communication issues. The stock also shows a high probability of further decline in the short term based on candlestick pattern analysis.

Financial Performance

No financial data available for analysis. The latest quarter financials could not be retrieved.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have lowered price targets from $23 to $17, then to $15, and most recently to $9. Despite these downgrades, some firms maintain an Overweight or Strong Buy rating, but concerns about growth, cash flow, and communication issues persist.

Wall Street analysts forecast LMRI stock price to rise
8 Analyst Rating
Wall Street analysts forecast LMRI stock price to rise
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.490
sliders
Low
22
Averages
22.71
High
23
Current: 9.490
sliders
Low
22
Averages
22.71
High
23
Barclays
Overweight
downgrade
$15 -> $9
AI Analysis
2026-05-20
Reason
Barclays
Price Target
$15 -> $9
AI Analysis
2026-05-20
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Lumexa Imaging to $9 from $15 and keeps an Overweight rating on the shares. The firm says RadNet is outperforming Lumexa on advanced volume growth and imaging segment pricing.
Barclays
Overweight
downgrade
$23 -> $15
2026-04-14
Reason
Barclays
Price Target
$23 -> $15
2026-04-14
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Lumexa Imaging to $15 from $23 and keeps an Overweight rating on the shares after meeting with management. The company reiterated its 2026 outlook, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LMRI
Unlock Now

People Also Watch